These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 34560013)

  • 41. Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial.
    Soumerai JD; Mato AR; Dogan A; Seshan VE; Joffe E; Flaherty K; Carter J; Hochberg E; Barnes JA; Hamilton AM; Abramson JS; Batlevi CL; Matasar MJ; Noy A; Owens CN; Palomba ML; Kumar A; Takvorian T; Ni A; Choma M; Friedman C; Chadha P; Simkins E; Ruiters J; Sechio S; Portman D; Ramos L; Nolet N; Mahajan N; Martignetti R; Mi J; Scorsune K; Lynch J; McGree B; Hughes S; Grieve C; Roeker LE; Thompson M; Johnson PC; Roshal M; Huang J; Biondo J; Wu Q; Jacob A; Abdel-Wahab O; Zelenetz AD
    Lancet Haematol; 2021 Dec; 8(12):e879-e890. PubMed ID: 34826411
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Nelarabine, intensive L-asparaginase, and protracted intrathecal therapy for newly diagnosed T-cell acute lymphoblastic leukaemia in children and young adults (ALL-T11): a nationwide, multicenter, phase 2 trial including randomisation in the very high-risk group.
    Sato A; Hatta Y; Imai C; Oshima K; Okamoto Y; Deguchi T; Hashii Y; Fukushima T; Hori T; Kiyokawa N; Kato M; Saito S; Anami K; Sakamoto T; Kosaka Y; Suenobu S; Imamura T; Kada A; Saito AM; Manabe A; Kiyoi H; Matsumura I; Koh K; Watanabe A; Miyazaki Y; Horibe K
    Lancet Haematol; 2023 Jun; 10(6):e419-e432. PubMed ID: 37167992
    [TBL] [Abstract][Full Text] [Related]  

  • 43. IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report.
    Martinelli G; Iacobucci I; Storlazzi CT; Vignetti M; Paoloni F; Cilloni D; Soverini S; Vitale A; Chiaretti S; Cimino G; Papayannidis C; Paolini S; Elia L; Fazi P; Meloni G; Amadori S; Saglio G; Pane F; Baccarani M; Foà R
    J Clin Oncol; 2009 Nov; 27(31):5202-7. PubMed ID: 19770381
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features. A case control study of the International BFM study group.
    Biondi A; Valsecchi MG; Seriu T; D'Aniello E; Willemse MJ; Fasching K; Pannunzio A; Gadner H; Schrappe M; Kamps WA; Bartram CR; van Dongen JJ; Panzer-Grümayer ER
    Leukemia; 2000 Nov; 14(11):1939-43. PubMed ID: 11069029
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prognostic value of rare IKZF1 deletion in childhood B-cell precursor acute lymphoblastic leukemia: an international collaborative study.
    Boer JM; van der Veer A; Rizopoulos D; Fiocco M; Sonneveld E; de Groot-Kruseman HA; Kuiper RP; Hoogerbrugge P; Horstmann M; Zaliova M; Palmi C; Trka J; Fronkova E; Emerenciano M; do Socorro Pombo-de-Oliveira M; Mlynarski W; Szczepanski T; Nebral K; Attarbaschi A; Venn N; Sutton R; Schwab CJ; Enshaei A; Vora A; Stanulla M; Schrappe M; Cazzaniga G; Conter V; Zimmermann M; Moorman AV; Pieters R; den Boer ML
    Leukemia; 2016 Jan; 30(1):32-8. PubMed ID: 26202931
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dasatinib with intensive chemotherapy in de novo paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (CA180-372/COG AALL1122): a single-arm, multicentre, phase 2 trial.
    Hunger SP; Tran TH; Saha V; Devidas M; Valsecchi MG; Gastier-Foster JM; Cazzaniga G; Reshmi SC; Borowitz MJ; Moorman AV; Heerema NA; Carroll AJ; Martin-Regueira P; Loh ML; Raetz EA; Schultz KR; Slayton WB; Cario G; Schrappe M; Silverman LB; Biondi A
    Lancet Haematol; 2023 Jul; 10(7):e510-e520. PubMed ID: 37407142
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Outcome of Down syndrome associated acute lymphoblastic leukaemia treated on a contemporary protocol.
    Patrick K; Wade R; Goulden N; Rowntree C; Hough R; Moorman AV; Mitchell CD; Vora A
    Br J Haematol; 2014 May; 165(4):552-5. PubMed ID: 24428704
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prospective use of molecular minimal residual disease for risk stratification in children and adolescents with acute lymphoblastic leukemia : Long-term results of the AIEOP-BFM ALL 2000 trial in Austria.
    Ronceray L; Dworzak M; Dieckmann K; Ebetsberger-Dachs G; Glogova E; Haas OA; Jones N; Nebral K; Moser R; Lion T; Meister B; Panzer-Grümayer R; Strehl S; Peters C; Pötschger U; Urban C; Mann G; Attarbaschi A;
    Wien Klin Wochenschr; 2024 Jul; 136(13-14):405-418. PubMed ID: 37535134
    [TBL] [Abstract][Full Text] [Related]  

  • 49. IKZF1 Deletions as a Prognostic Factor in Costa Rican Patients With Pediatric B-Cell Acute Lymphoblastic Leukemia.
    Granados-Zamora M; Chaves-Herrera K; Morera-Araya E; Granados-Alfaro P; Valverde-Muñoz K; Soto-Herrera G; Santamaría-Quesada C
    J Pediatr Hematol Oncol; 2020 Aug; 42(6):e401-e406. PubMed ID: 32324698
    [TBL] [Abstract][Full Text] [Related]  

  • 50. IGH@ translocations, CRLF2 deregulation, and microdeletions in adolescents and adults with acute lymphoblastic leukemia.
    Moorman AV; Schwab C; Ensor HM; Russell LJ; Morrison H; Jones L; Masic D; Patel B; Rowe JM; Tallman M; Goldstone AH; Fielding AK; Harrison CJ
    J Clin Oncol; 2012 Sep; 30(25):3100-8. PubMed ID: 22851563
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Refining risk classification in childhood B acute lymphoblastic leukemia: results of DFCI ALL Consortium Protocol 05-001.
    Vrooman LM; Blonquist TM; Harris MH; Stevenson KE; Place AE; Hunt SK; O'Brien JE; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Sulis ML; Welch JJG; Neuberg DS; Sallan SE; Silverman LB
    Blood Adv; 2018 Jun; 2(12):1449-1458. PubMed ID: 29941458
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prognosis of pediatric BCP-ALL with IKZF1 deletions and impact of intensive chemotherapy: Results of SCCLG-2016 study.
    Lin S; Liao N; Li X; Yang L; He YY; Tang YL; Wan WQ; Jia W; Zhang YJ; Kong Q; Long X; Lan X; Ling YY; Lin D; Zhang XL; Wen C; Li CK; Xu HG
    Eur J Haematol; 2024 Sep; 113(3):357-370. PubMed ID: 38847134
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Integrated use of minimal residual disease classification and IKZF1 alteration status accurately predicts 79% of relapses in pediatric acute lymphoblastic leukemia.
    Waanders E; van der Velden VH; van der Schoot CE; van Leeuwen FN; van Reijmersdal SV; de Haas V; Veerman AJ; van Kessel AG; Hoogerbrugge PM; Kuiper RP; van Dongen JJ
    Leukemia; 2011 Feb; 25(2):254-8. PubMed ID: 21102428
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prognostic impact of IKZF1 deletion in adults with common B-cell acute lymphoblastic leukemia.
    Yao QM; Liu KY; Gale RP; Jiang B; Liu YR; Jiang Q; Jiang H; Zhang XH; Zhang MJ; Chen SS; Huang XJ; Xu LP; Ruan GR
    BMC Cancer; 2016 Apr; 16():269. PubMed ID: 27067989
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Effect of increasing the intensity of chemotherapy on the prognosis of acute lymphoblastic leukemia in children with IKZF1 deletion].
    Zheng YZ; Li J; LE SH; Zheng H; Hua XL; Chen ZS; Hu JD
    Zhongguo Dang Dai Er Ke Za Zhi; 2019 Jul; 21(7):690-695. PubMed ID: 31315770
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pre- and post-transplant minimal residual disease predicts relapse occurrence in children with acute lymphoblastic leukaemia.
    Lovisa F; Zecca M; Rossi B; Campeggio M; Magrin E; Giarin E; Buldini B; Songia S; Cazzaniga G; Mina T; Acquafredda G; Quarello P; Locatelli F; Fagioli F; Basso G
    Br J Haematol; 2018 Mar; 180(5):680-693. PubMed ID: 29359790
    [TBL] [Abstract][Full Text] [Related]  

  • 57. IKZF1 Gene Deletion in Pediatric Patients Diagnosed with Acute Lymphoblastic Leukemia in Mexico.
    Ayón-Pérez MF; Pimentel-Gutiérrez HJ; Durán-Avelar MJ; Vibanco-Pérez N; Pérez-Peraza VM; Pérez-González ÓA; Barrientos-Ríos R; Santillán-Ávila CF; Zambrano-Zaragoza JF; Agraz-Cibrián JM; Gutiérrez-Franco J; Vázquez-Reyes A
    Cytogenet Genome Res; 2019; 158(1):10-16. PubMed ID: 30974435
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A risk score including microdeletions improves relapse prediction for standard and medium risk precursor B-cell acute lymphoblastic leukaemia in children.
    Sutton R; Venn NC; Law T; Boer JM; Trahair TN; Ng A; Den Boer ML; Dissanayake A; Giles JE; Dalzell P; Mayoh C; Barbaric D; Revesz T; Alvaro F; Pieters R; Haber M; Norris MD; Schrappe M; Dalla Pozza L; Marshall GM
    Br J Haematol; 2018 Feb; 180(4):550-562. PubMed ID: 29194562
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood.
    van Dongen JJ; Seriu T; Panzer-Grümayer ER; Biondi A; Pongers-Willemse MJ; Corral L; Stolz F; Schrappe M; Masera G; Kamps WA; Gadner H; van Wering ER; Ludwig WD; Basso G; de Bruijn MA; Cazzaniga G; Hettinger K; van der Does-van den Berg A; Hop WC; Riehm H; Bartram CR
    Lancet; 1998 Nov; 352(9142):1731-8. PubMed ID: 9848348
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Excellent outcome of minimal residual disease-defined low-risk patients is sustained with more than 10 years follow-up: results of UK paediatric acute lymphoblastic leukaemia trials 1997-2003.
    Bartram J; Wade R; Vora A; Hancock J; Mitchell C; Kinsey S; Steward C; Moppett J; Goulden N
    Arch Dis Child; 2016 May; 101(5):449-54. PubMed ID: 26865705
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.